| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia (NCT07169331) | BeiGene | 2025-10-17 |
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis (NCT07100938) | BeiGene | 2025-08-21 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (NCT07005713) | BeiGene | 2025-07-19 |
| Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (NCT06906809) | BeiGene | 2025-04-03 |
| A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants (NCT06776679) | BeiGene | 2025-01-24 |
| A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants (NCT06761898) | BeiGene | 2025-01-14 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (NCT06540066) | BeiGene | 2024-09-11 |
| A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers (NCT06543043) | BeiGene | 2024-08-19 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases (NCT06342713) | BeiGene | 2024-06-20 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (NCT06257264) | BeiGene | 2024-03-11 |
| Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants (NCT05644626) | BeiGene | 2024-03-01 |
| Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NCT06091943) | BeiGene | 2023-11-16 |
| A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (NCT06010303) | BeiGene | 2023-11-08 |
| A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (NCT06029127) | BeiGene | 2023-10-23 |
| BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (NCT05935098) | BeiGene | 2023-08-21 |
| A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (NCT05909904) | BeiGene | 2023-08-02 |
| A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (NCT05904496) | BeiGene | 2023-07-19 |
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma (NCT05564338) | BeiGene | 2023-06-30 |
| A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417 (NCT05844111) | BeiGene | 2023-05-22 |
| Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants (NCT05767398) | BeiGene | 2023-03-07 |
| A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (NCT05635708) | BeiGene | 2023-03-07 |
| Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia (NCT05640102) | BeiGene | 2023-03-03 |
| A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (NCT05609370) | BeiGene | 2023-01-29 |
| A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors. (NCT05661955) | BeiGene | 2023-01-09 |
| Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT05479994) | BeiGene | 2022-10-25 |
| Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma (NCT05461794) | BeiGene | 2022-10-03 |
| Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma (NCT05471843) | BeiGene | 2022-09-05 |
| Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors (NCT05494762) | BeiGene | 2022-08-25 |
| Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma (NCT05373901) | BeiGene | 2022-06-07 |
| Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults (NCT05547399) | BeiGene | 2022-06-07 |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731) | BeiGene | 2022-05-06 |
| Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab (NCT05267054) | BeiGene | 2022-04-25 |
| Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects (NCT05387668) | BeiGene | 2022-02-17 |
| Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer (NCT05116085) | BeiGene | 2022-01-26 |
| Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NCT05014815) | BeiGene | 2021-11-16 |
| First-in-Human, Single- and Multiple-Ascending Dose and Food-Effect Study of BGB-23339 in Healthy Participants (NCT05093270) | BeiGene | 2021-11-15 |
| To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors (NCT05014828) | BeiGene | 2021-09-18 |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (NCT04948697) | BeiGene | 2021-08-20 |
| Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma (NCT04974047) | BeiGene | 2021-08-17 |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib (NCT05068440) | BeiGene | 2021-08-11 |
| Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04921358) | BeiGene | 2021-07-27 |
| Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer (NCT04952597) | BeiGene | 2021-07-15 |
| Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies (NCT04883957) | BeiGene | 2021-07-05 |
| A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer (NCT04866017) | BeiGene | 2021-06-17 |
| A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer (NCT04746924) | BeiGene | 2021-05-24 |
| Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors (NCT04716634) | BeiGene | 2021-04-19 |
| Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (NCT04732494) | BeiGene | 2021-03-31 |
| BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors (NCT04649385) | BeiGene | 2021-03-04 |
| AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer (NCT04693234) | BeiGene | 2021-02-15 |
| Zanubrutinib in Participants With Active Proliferative Lupus Nephritis (NCT04643470) | BeiGene | 2020-12-22 |
| Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma (NCT04486391) | BeiGene | 2020-12-14 |
| BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants (NCT04669262) | BeiGene | 2020-12-09 |
| Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (NCT04551898) | BeiGene | 2020-12-02 |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies (NCT04551963) | BeiGene | 2020-11-15 |
| Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04436107) | BeiGene | 2020-09-11 |
| Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants (NCT04532294) | BeiGene | 2020-09-08 |
| Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma (NCT04401800) | BeiGene | 2020-09-04 |
| Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT04318080) | BeiGene | 2020-08-20 |
| The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males (NCT04470908) | BeiGene | 2020-07-29 |
| Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults (NCT04472650) | BeiGene | 2020-07-23 |
| Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants (NCT04382586) | BeiGene | 2020-07-06 |
| Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (NCT04379635) | BeiGene | 2020-05-29 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab (NCT04276493) | BeiGene | 2020-03-26 |
| Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies (NCT04172246) | BeiGene | 2020-01-29 |
| Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies (NCT04170283) | BeiGene | 2020-01-16 |
| Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (NCT04116437) | BeiGene | 2019-10-15 |
| Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors (NCT04047862) | BeiGene | 2019-08-15 |
| Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (NCT04005716) | BeiGene | 2019-07-22 |
| A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma (NCT03957590) | BeiGene | 2019-06-11 |
| Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer (NCT03994211) | BeiGene | 2019-05-29 |
| Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma (NCT03967977) | BeiGene | 2019-05-29 |
| Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer (NCT03991494) | BeiGene | 2019-05-29 |
| Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (NCT03924986) | BeiGene | 2019-03-27 |
| A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer (NCT03941873) | BeiGene | 2019-02-28 |
| Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma (NCT03846427) | BeiGene | 2019-02-19 |
| Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency (NCT03712930) | BeiGene | 2019-02-05 |
| Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma (NCT03777657) | BeiGene | 2018-12-13 |
| A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma (NCT03783442) | BeiGene | 2018-12-11 |
| Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors (NCT03744468) | BeiGene | 2018-11-13 |
| A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Participants With Advanced Solid Tumors (NCT03666143) | BeiGene | 2018-11-01 |
| A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT03734016) | BeiGene | 2018-11-01 |
| Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors (NCT03736889) | BeiGene | 2018-09-19 |
| A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer (NCT03594747) | BeiGene | 2018-07-30 |
| Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer (NCT03427814) | BeiGene | 2018-07-03 |
| Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China (NCT03575065) | BeiGene | 2018-06-22 |
| A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects (NCT03561298) | BeiGene | 2018-06-07 |
| Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function (NCT03465059) | BeiGene | 2018-05-30 |
| Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (NCT03519230) | BeiGene | 2018-05-14 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451) | BeiGene | 2018-04-13 |
| Study of BGB-A317 in Participants With Previously Treated Unresectable HCC (NCT03419897) | BeiGene | 2018-04-09 |
| A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma (NCT03430843) | BeiGene | 2018-01-26 |
| A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects (NCT03432884) | BeiGene | 2018-01-25 |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) (NCT03520920) | BeiGene | 2018-01-04 |
| A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) (NCT03412773) | BeiGene | 2017-12-18 |
| Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03358875) | BeiGene | 2017-11-30 |
| Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors (NCT03379259) | BeiGene | 2017-11-27 |
| A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma (NCT03332017) | BeiGene | 2017-11-14 |
| A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (NCT03336333) | BeiGene | 2017-10-31 |
| Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects (NCT03301181) | BeiGene | 2017-09-18 |